key: cord-0847610-4nxok014
authors: Masset, Christophe; Lebot-Bouras, Sabine; Branchereau, Julien; Renaudin, Karine; Cantarovich, Diego
title: Pancreas allograft rejection occurring after ChAdOx1 nCoV-19 vaccine
date: 2021-11-12
journal: Diabetes Metab
DOI: 10.1016/j.diabet.2021.101303
sha: 44521e10820acbe0e5db715ce4dd8771d52e8c71
doc_id: 847610
cord_uid: 4nxok014

nan

To the editor, Solid organ transplant recipients are at high risk of developing severe forms of Covid-19 infection, requiring urgent access to vaccination [1] . mRNA vaccines are recommended for this population [2] , but due to vaccine shortage in Europe, some patients were vaccinated using ChAdOx1 nCoV-19 (AstraZeneca). We report the case of a 51-year-old woman, recipient of a pancreas allograft 6 years ago because of type 1 diabetes. The patient was insulin-free on maintenance tacrolimus and mycophenolic acid. Pancreas function was optimal, as reflected by a glycemia at 4.5 mmol/l (normal range 4.1 to 5.9 mmol/l) and a C-peptide at 2 ng/mL (normal range 0.4 to 4 ng/ml) on March 6, 2021. There were no reported issues of therapeutic adherence, immunosuppressive drugs were well tolerated and CNI trough levels were stable around 8ng/ml since the first months of transplantation. She received a first dose of ChAdOx1 nCoV-19 on March 12, 2021 and developed weakness and fever (38°C) afterward, for 12 hours. On May 4, 2021, she experienced polyuria and polydipsia requiring admission to hospital. Laboratory tests revealed hyperglycemia at 27 mmol/l, associated with ketoacidosis, elevation of lipasemia (181 IU/l, normal range 0 to 60 IU/l) and an abrupt decline of the C-peptide level to 0.1 ng/ml ( Figure   1 ). There was evidence of an eosinophilia at 2,000/mm 3 , without features of parasitic infection nor recent drug introduction. SARS-Cov-2 serology was negative (electrochemiluminescence immunoassay, Roche Elecsys ® ). Auto-antibodies anti-ZnT8 were positive at 159 IU/ml (normal range < 15 IOU/ml), anti-GAD 65 were positive at 6.3 IU/ml (normal range < 5 IU/ml), anti-islet cell antibodies were positive at 160 IU/ml (normal range < 5 IU/ml); anti IA2 and anti-insulin antibodies were negative. Computed tomography did not show any evidence of pancreas allograft thrombosis. Pancreas transplant biopsy revealed grade II acute rejection without any feature of antibody-mediated rejection (C4d negative) or significant islet alteration (Figure 2 ). There were no circulating donor specific antibodies, as there was no evidence for histological recurrence of diabetes mellitus nor toxicity of tacrolimus.

Immediate treatment including high-dose pulse steroids and anti-thymocyte globulins was initiated, with resolution of eosinophilia, but without significant impact on glycemic control; the patient remained insulin-dependent. Data were extracted from the French DIVAT cohort (www.divat.fr, approved by the national authorities, CNIL, n°914184) consisting of transplant recipients monitored in Nantes. The quality of the DIVAT data bank is validated by an annual cross-center audit, and all participants gave informed consent.

To our knowledge, this is the first report of pancreas allograft rejection following Covid-19 vaccine. Presence of eosinophilia may suggest a delayed allergic response which could have triggered a larger immune response leading to allograft rejection, but can also directly reflect allograft rejection [3, 4] . Currently, there are only two reports of allograft rejection following Covid-19 vaccine: kidney [5] and liver [6] rejection. Both were acute severe rejections consecutive to mRNA vaccines, with partial recuperation of allograft functions. Of note, presence of autoantibodies usually found in type 1 diabetes may suggest a part of auto-immune reactivity even if the biopsy did not show any typical characteristics [7] . Although the benefit of Covid-19 vaccination seems unquestionable for solid organ transplant recipients, these reports added to ours highlight the need for close follow-up to assess potential immune adverse events, such as acute rejection. 

An initial report from the French SOT COVID Registry suggests high mortality due to Covid-19 in recipients of kidney transplants

Recommendations for the use of COVID-19 vaccines in patients with immune-mediated kidney diseases

Banff schema for grading pancreas allograft rejection: working proposal by a multi-disciplinary international consensus panel

Eosinophilia as an early indicator of pancreatic allograft rejection: Eosinophilia and pancreas graft rejection

Acute rejection after anti-SARS-CoV-2 mRNA vaccination in a patient who underwent a kidney transplant

Steroid-resistant acute cellular rejection of the liver after severe acute respiratory syndrome coronavirus 2 mrna vaccination

Zinc Transporter 8 autoantibodies increase the predictive value of islet autoantibodies for function loss of technically successful solitary pancreas transplant